ArticleDiabetology international2026
Low serum free testosterone is independently associated with sarcopenic obesity in males with type 2 diabetes: a post hoc cross-sectional analysis from the impact of diabetes mellitus on dynapenia study.
Article in Diabetology international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aims: Testosterone plays a key role in maintaining skeletal muscle mass, strength, and overall physical function, while also preventing excess fat accumulation. However, limited evidence focusing specifically on free testosterone and sarcopenic obesity in males with type 2 diabetes (T2D) is available. This study aimed to investigate the association between serum free testosterone and sarcopenic obesity in males with T2D according to the newly established Japanese consensus definition. Methods: This post hoc cross-sectional analysis used data from the multicenter, cross-sectional Impact of Diabetes Mellitus on Dynapenia study. Sarcopenic obesity was defined based on the Japanese Working Group on Sarcopenic Obesity criteria as the combination of a high body mass index (BMI) or waist circumference with low grip strength, high body fat percentage, and low appendicular skeletal muscle mass adjusted for BMI. Serum free testosterone was measured, and multivariate logistic regression analysis was used to evaluate the association with sarcopenic obesity. Results: Males with sarcopenic obesity had significantly lower serum free testosterone than those without sarcopenic obesity ( Conclusions: Low serum free testosterone is independently associated with sarcopenic obesity in males with T2D. Supplementary Information: The online version contains supplementary material available at https://doi.org/10.1007/s13340-026-00929-y.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.